Projects per year
Personal profile
Research Strategic Pillar
Dr. Randall Urban, VP and Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
Dive into the research topics where Xuping Xie is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
-
SAVE Variant Pipeline-SARS-CoV-2 variants serum neutralization analysis
Xie, X. (PI)
American Type Culture Collection
9/26/23 → 9/25/28
Project: Research project
-
Inhibitory activities of compounds against flaviviruses
Xie, X. (PI)
3/2/23 → 12/31/24
Project: Research project
-
Perform testing in support of PFIZER pre-clinical anti-SARS-CoV-2 mAb program as directed by PFIZER
Xie, X. (PI)
12/7/22 → 3/7/25
Project: Research project
-
Involving the testing of compounds against SARS-CoV-2
Xie, X. (PI)
10/25/22 → 12/31/24
Project: Research project
-
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Alugubelli, Y. R., Xiao, J., Khatua, K., Kumar, S., Sun, L., Ma, Y., Ma, X. R., Vulupala, V. R., Atla, S., Blankenship, L. R., Coleman, D., Xie, X., Neuman, B. W., Liu, W. R. & Xu, S., Apr 25 2024, In: Journal of medicinal chemistry. 67, 8, p. 6495-6507 13 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations -
Integrated multi-omics analyses identify anti-viral host factors and pathways controlling SARS-CoV-2 infection
Hou, J., Wei, Y., Zou, J., Jaffery, R., Sun, L., Liang, S., Zheng, N., Guerrero, A. M., Egan, N. A., Bohat, R., Chen, S., Zheng, C., Mao, X., Yi, S. S., Chen, K., McGrail, D. J., Sahni, N., Shi, P.-Y., Chen, Y. & Xie, X. & 1 others, , Jan 2 2024, In: Nature communications. 15, 1, p. 109 109.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery
Bolinger, A. A., Li, J., Xie, X., Li, H. & Zhou, J., 2024, In: Expert Opinion on Drug Discovery. 19, 9, p. 1023-1041 19 p.Research output: Contribution to journal › Article › peer-review
-
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
Zhang, L., Xie, X., Luo, H., Qian, R., Yang, Y., Yu, H., Huang, J., Shi, P.-Y. & Hu, Q., Dec 2024, In: Cell Discovery. 10, 1, 40.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial
on behalf of the C4591054 Study Group, Feb 2024, In: Vaccines. 12, 2, 118.Research output: Contribution to journal › Article › peer-review
Open Access9 Scopus citations